File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Polysaccharopeptide enhances the anticancer activity of doxorubicin and etoposide on human breast cancer cells ZR-75-30

TitlePolysaccharopeptide enhances the anticancer activity of doxorubicin and etoposide on human breast cancer cells ZR-75-30
Authors
KeywordsBromodeoxyuridine
Chinese medicinal mushroom
Cytarabine
Doxorubicin
Etoposide
Human breast cancer
Polysaccharopeptide
Issue Date2008
PublisherSpandidos Publications. The Journal's web site is located at http://www.spandidos-publications.com/ijo/
Citation
International Journal Of Oncology, 2008, v. 32 n. 3, p. 689-699 How to Cite?
AbstractIn search of natural bioactive microbial compounds with adjuvant properties, we have previously showed that the polysaccharopeptide (PSP), isolated from Chinese medicinal mushroom Coriolus versicolor, was able to enhance the cytotoxicity of certain S-phase targeted-drugs on human leukemic HL-60 cells via some cell-cycle and apoptotic-dependent pathways. The present study aimed to investigate whether the synergism of mechanisms of PSP with certain chemotherapeutic drugs also applies to human breast cancer. PSP treatment enhanced the cytotoxicity of doxorubicin (Doxo), etoposide (VP-16) but not cytarabine (Ara-C). Bivariate bromodeoxyuridine (BrdUrd)/DNA flow cytometry analysis estimated a longer DNA synthesis time (Ts) for the PSP treated cancerous cells suggesting that PSP enhanced the apoptotic effect of Doxo and VP-16 via creating an S-phase trap in the human breast cancer cell line ZR-75-30. The participation of PSP in the apoptotic machinery of the chemotherapeutic agents was further supported by a reduced ratio of protein expression of Bcl-xL/Bax of the cancer cells. This study provides further insight into the synergistic mechanisms of PSP and supports the hypothesis that the anti-cancer potentials of PSP is not limited to leukemia but may also be used as an adjuvant therapy for breast cancers.
Persistent Identifierhttp://hdl.handle.net/10722/89297
ISSN
2023 Impact Factor: 4.5
2023 SCImago Journal Rankings: 1.099
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorWan, JMFen_HK
dc.contributor.authorSit, WHen_HK
dc.contributor.authorLouie, JCYen_HK
dc.date.accessioned2010-09-06T09:55:04Z-
dc.date.available2010-09-06T09:55:04Z-
dc.date.issued2008en_HK
dc.identifier.citationInternational Journal Of Oncology, 2008, v. 32 n. 3, p. 689-699en_HK
dc.identifier.issn1019-6439en_HK
dc.identifier.urihttp://hdl.handle.net/10722/89297-
dc.description.abstractIn search of natural bioactive microbial compounds with adjuvant properties, we have previously showed that the polysaccharopeptide (PSP), isolated from Chinese medicinal mushroom Coriolus versicolor, was able to enhance the cytotoxicity of certain S-phase targeted-drugs on human leukemic HL-60 cells via some cell-cycle and apoptotic-dependent pathways. The present study aimed to investigate whether the synergism of mechanisms of PSP with certain chemotherapeutic drugs also applies to human breast cancer. PSP treatment enhanced the cytotoxicity of doxorubicin (Doxo), etoposide (VP-16) but not cytarabine (Ara-C). Bivariate bromodeoxyuridine (BrdUrd)/DNA flow cytometry analysis estimated a longer DNA synthesis time (Ts) for the PSP treated cancerous cells suggesting that PSP enhanced the apoptotic effect of Doxo and VP-16 via creating an S-phase trap in the human breast cancer cell line ZR-75-30. The participation of PSP in the apoptotic machinery of the chemotherapeutic agents was further supported by a reduced ratio of protein expression of Bcl-xL/Bax of the cancer cells. This study provides further insight into the synergistic mechanisms of PSP and supports the hypothesis that the anti-cancer potentials of PSP is not limited to leukemia but may also be used as an adjuvant therapy for breast cancers.en_HK
dc.languageengen_HK
dc.publisherSpandidos Publications. The Journal's web site is located at http://www.spandidos-publications.com/ijo/en_HK
dc.relation.ispartofInternational Journal of Oncologyen_HK
dc.subjectBromodeoxyuridineen_HK
dc.subjectChinese medicinal mushroomen_HK
dc.subjectCytarabineen_HK
dc.subjectDoxorubicinen_HK
dc.subjectEtoposideen_HK
dc.subjectHuman breast canceren_HK
dc.subjectPolysaccharopeptideen_HK
dc.subject.meshBreast Neoplasms - pathology-
dc.subject.meshCarcinoma, Ductal, Breast - pathology-
dc.subject.meshDoxorubicin - pharmacology-
dc.subject.meshEtoposide - pharmacology-
dc.subject.meshProteoglycans - pharmacology-
dc.titlePolysaccharopeptide enhances the anticancer activity of doxorubicin and etoposide on human breast cancer cells ZR-75-30en_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1019-6439&volume=32&issue=3&spage=689&epage=699&date=2008&atitle=Polysaccharopeptide+enhances+the+anticancer+activity+of+doxorubicin+and+etoposide+on+human+breast+cancer+cells+ZR-75-30en_HK
dc.identifier.emailWan, JMF: jmfwan@hku.hken_HK
dc.identifier.authorityWan, JMF=rp00798en_HK
dc.description.naturelink_to_OA_fulltext-
dc.identifier.pmid18292947-
dc.identifier.scopuseid_2-s2.0-40249088760en_HK
dc.identifier.hkuros151665en_HK
dc.identifier.volume32en_HK
dc.identifier.issue3en_HK
dc.identifier.spage689en_HK
dc.identifier.epage699en_HK
dc.identifier.isiWOS:000253507600020-
dc.publisher.placeGreeceen_HK
dc.identifier.scopusauthoridWan, JMF=8930305000en_HK
dc.identifier.scopusauthoridSit, WH=8528923000en_HK
dc.identifier.scopusauthoridLouie, JCY=25931640600en_HK
dc.identifier.issnl1019-6439-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats